Sermorelin 2mg research peptide UK (GRF 1-29) is the most physiologically representative GHRH analogue, with no structural modifications and the shortest in vitro half-life at approximately 12 minutes for precise pulsatile GH pharmacokinetic studies. ≥98% purity. Janoshik tested. Research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
SERMORELIN 2mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
Sermorelin 2mg Research Peptide UK
Sermorelin 2mg, also known as GRF 1-29 NH2 and GHRH(1-29)NH2, is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of native Growth Hormone Releasing Hormone with no structural modifications. Molecular formula C149H246N44O42S, molecular weight 3,357.93 Da. It is the most structurally conservative GHRH research analogue investigated in experimental research and the only one that carries no DPP-IV protection beyond the native peptide sequence itself.
This structural conservatism produces the defining pharmacokinetic property of the sermorelin 2mg research peptide: an in vitro half-life of approximately 12 minutes, the shortest of all GHRH research analogues. This rapid clearance generates the most precisely pulsatile GH secretion pattern of any GHRH research peptide, making it the preferred compound for pharmacokinetic time-course studies, GH pulse frequency and amplitude investigations, and any research question requiring native-like GHRH kinetic behaviour without the extended DPP-IV protection introduced by CJC-1295 Without DAC 10mg or the N-terminal modification of Tesamorelin 5mg.
For researchers designing GHRH analogue comparison studies, sermorelin 2mg occupies the unmodified reference position. CJC-1295 Without DAC 10mg provides the DPP-IV-resistant modified 29-amino acid comparison, while Tesamorelin 5mg provides the full 44-amino acid comparison. Running all three as independent treatment arms allows researchers to dissect the contribution of sequence length, DPP-IV resistance, and N-terminal modification to receptor engagement and GH secretion dynamics. For GHRP complement in combined pulsatile research, Ipamorelin 5mg targets GHS-R1a independently of the GHRHR pathway.
The 2mg format is appropriate for pilot investigations, pharmacokinetic time-course assays where multiple time-point samples require limited compound volume per arm, and first-time sermorelin research. For established programmes requiring extended multi-arm designs, Sermorelin 5mg provides the advanced format. Sermorelin’s moderate DPP-IV sensitivity means reconstituted solution should be aliquoted immediately and used promptly within protocol timelines.
Full mechanism, half-life comparison across GHRH analogues, and protocol guidance are available in the sermorelin 2mg research guide on the Ascend Peptides UK blog.
All batches tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirmed at C149H246N44O42S, 3,357.93 Da. Verifiable CoA.
For laboratory handling purposes, the lyophilised material may be reconstituted using bacteriostatic water or another suitable buffered aqueous solution depending on analytical protocol requirements. Store lyophilised material at -20°C and avoid repeated freeze-thaw cycles.
WADA Status: Prohibited at all times.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
